Roche said it will stop development of emugrobart after the drug failed to consistently improve muscle growth and motor function in a key study. The Swiss pharma notified European patients in a letter explaining the decision and its clinical rationale. Genentech, a Roche unit, separately shelved a related muscle‑preserving candidate in two rare genetic disease programs after the molecule failed to achieve the desired muscle gains. Both terminations raise questions about translatability from early biology to clinical benefit in muscle‑building approaches. The program closures may have downstream implications for trials testing similar mechanisms in broader indications, including obesity, and will prompt re‑evaluation of clinical strategies in musculoskeletal drug development.